---
layout: default
title: Migalastat Hydrochloride
parent: 僅模型預測 (L5)
nav_order: 292
evidence_level: L5
indication_count: 0
---

# Migalastat Hydrochloride
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Migalastat Hydrochloride: Drug Repurposing Evaluation — Insufficient Evidence Package

## One-Sentence Summary

Migalastat Hydrochloride is a drug for which no original indication data was retrieved in the current evidence package.
The TxGNN model returned **no predicted new indications** for this compound, and the drug is currently **not marketed in Denmark**.
This report therefore serves as a data-gap notification rather than a full repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current data |
| Predicted New Indication | No predictions returned by TxGNN |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 – Model prediction only (no predictions available) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction is available for Migalastat Hydrochloride in the current evidence package. As a result, no mechanistic or indication-linkage analysis can be performed at this stage.

Currently, detailed mechanism of action data is not available (recorded as a high-severity data gap, DG002). Without MOA information, it is not possible to reason about whether the drug's pharmacological profile could translate to any new indication.

Additionally, no original approved indications were retrieved from the Danish Medicines Agency (Lægemiddelstyrelsen) or any other source in this package. Until the drug's original therapeutic context is confirmed, any repurposing hypothesis would lack a mechanistic anchor.

---

## Clinical Trial Evidence

Currently no related clinical trials registered in this evidence package.

---

## Literature Evidence

Currently no related literature available in this evidence package.

---

## Denmark Market Information

Migalastat Hydrochloride holds **no marketing authorisations** in Denmark. No product records were returned from the Lægemiddelstyrelsen dataset.

---

## Safety Considerations

> Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

All safety fields — including key warnings, contraindications, and drug–drug interactions — were returned as data gaps (DG001, severity: Blocking) or were not found in the query log. No safety data can therefore be summarised here.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The evidence package is critically incomplete: no TxGNN predictions were generated, no original indication was recorded, MOA data is missing, and no marketing authorisation exists in Denmark. Proceeding to any repurposing evaluation is not possible without first resolving the blocking data gaps.

**To proceed, the following is needed:**

- **Resolve DG001 (Blocking):** Obtain the full SmPC/product information sheet to extract approved indications, warnings, and contraindications. Recommended source: the EMA product page or national competent authority register.
- **Resolve DG002 (High):** Query the DrugBank API for the confirmed DrugBank ID to retrieve the mechanism of action and pharmacological category.
- **Confirm drug identity:** Verify whether "Migalastat Hydrochloride" maps to a DrugBank entry (query returned 1 result on 2026-03-26, but no ID was stored); confirm the DrugBank ID and re-run the TxGNN prediction pipeline.
- **Re-run TxGNN:** Once drug identity and MOA are confirmed, re-execute the knowledge-graph and deep-learning prediction steps to generate a ranked indication list.
- **Re-submit evidence package:** After all blocking and high-severity gaps are resolved, regenerate the evidence pack (version ≥ v5) and resubmit for full evaluation.

---

*This report is generated for research reference purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application.*
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

